- Home
- URGN vs GHG Comparison
URGN vs GHG Comparison
Compare URGN & GHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- GHG
- Stock Information
- Founded
- URGN 2004
- GHG 2004
- Country
- URGN United States
- GHG China
- Employees
- URGN N/A
- GHG N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- GHG Hotels/Resorts
- Sector
- URGN Health Care
- GHG Consumer Discretionary
- Exchange
- URGN Nasdaq
- GHG Nasdaq
- Market Cap
- URGN 181.2M
- GHG 202.0M
- IPO Year
- URGN 2017
- GHG 2018
- Fundamental
- Price
- URGN $13.84
- GHG $2.34
- Analyst Decision
- URGN Strong Buy
- GHG
- Analyst Count
- URGN 8
- GHG 0
- Target Price
- URGN $29.00
- GHG N/A
- AVG Volume (30 Days)
- URGN 4.3M
- GHG 12.9K
- Earning Date
- URGN 08-12-2025
- GHG 08-14-2025
- Dividend Yield
- URGN N/A
- GHG 4.41%
- EPS Growth
- URGN N/A
- GHG N/A
- EPS
- URGN N/A
- GHG 0.15
- Revenue
- URGN $91,871,000.00
- GHG $184,055,595.00
- Revenue This Year
- URGN $36.65
- GHG $19.02
- Revenue Next Year
- URGN $88.35
- GHG $8.26
- P/E Ratio
- URGN N/A
- GHG $15.29
- Revenue Growth
- URGN 8.98
- GHG N/A
- 52 Week Low
- URGN $3.42
- GHG $1.93
- 52 Week High
- URGN $18.15
- GHG $3.40
- Technical
- Relative Strength Index (RSI)
- URGN 64.90
- GHG 58.13
- Support Level
- URGN $13.26
- GHG $1.97
- Resistance Level
- URGN $13.94
- GHG $2.46
- Average True Range (ATR)
- URGN 0.91
- GHG 0.12
- MACD
- URGN -0.08
- GHG 0.02
- Stochastic Oscillator
- URGN 44.44
- GHG 61.80
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.